Form 4: PROCEPT BioRobotics Director Sells Over 75,000 Shares Under Pre-Arranged Trading Plan

Antal Rohit Desai, a Director at PROCEPT BioRobotics Corp., sold 75,000 shares of common stock in early June 2025, pursuant to a Rule 10b5-1 trading plan established in November 2024.

Summary

• Antal Rohit Desai, a Director of PROCEPT BioRobotics Corp. (PRCT), sold a total of 75,000 shares of common stock between June 3, 2025, and June 5, 2025.
• The sales were executed at weighted average prices ranging from approximately $58.04 to $66.73 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which was adopted by Mr. Desai on November 5, 2024.
• Following these sales, Mr. Desai's indirect beneficial ownership through The 2:22 DNA Trust decreased from an estimated 164,363 shares to 89,363 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the execution under a pre-arranged Rule 10b5-1 plan mitigates concerns that the sales are based on new, negative material non-public information. It suggests a planned diversification or liquidity event rather than a bearish signal.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not a reaction to recent non-public information, which can mitigate negative interpretations of insider selling.

Negatives

• A significant reduction in insider ownership by a director, with 75,000 shares sold, representing a decrease from 164,363 shares to 89,363 shares.
• Insider selling, even under a 10b5-1 plan, reduces the alignment of interests between the insider and common shareholders.

Risks

• Potential negative market perception due to a director's significant share sales, despite the existence of a 10b5-1 plan.

Future Outlook

NA

Management Comments

• "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 5, 2024."
• "The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."

Industry Context

This Form 4 filing is specific to PROCEPT BioRobotics Corp. and its director's stock transactions, and does not provide broader industry context or trends.

Related Party Transactions

• The shares sold were indirectly beneficially owned by Antal Rohit Desai through The 2:22 DNA Trust, indicating a transaction involving a related party (the trust controlled by the reporting person).

Stakeholder Impact

• Shareholders: May view the reduction in director ownership with caution, though the 10b5-1 plan provides a neutral context.
• Employees, Customers, Suppliers, Creditors: Unlikely to be directly impacted by this specific insider trading disclosure.

Key Dates

Keywords

PROCEPT BioRobotics, PRCT, Antal Rohit Desai, Insider Selling, Form 4, Rule 10b5-1, Stock Sales, Director, Beneficial Ownership